Evolent Health Inc - Class A
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.36%.
Did EVH Beat Earnings? Q2 2025 Results
Evolent Health delivered a disappointing second quarter, missing on both the top and bottom lines as a sharp contraction in its Performance Suite business weighed heavily on results. Revenue fell 31.3% year-over-year to $444.33 million, trailing the $459.43 million consensus by 3.29%, while the company posted an adjusted loss of $0.10 per share, a stark reversal from $0.18 in adjusted earnings a year ago and well below the $0.08 consensus estimate, representing a 223.30% miss. The primary culprit was a dramatic decline in Performance Suite PMPM fees, which dropped to $13.76 from $22.30 in the year-ago period alongside a reduction in lives on platform, collectively driving the revenue base sharply lower. On a brighter note, adjusted EBITDA margin edged up to 8.5% from 8.0%, signaling improved cost discipline despite the revenue headwinds. The company also recently priced $145 million in convertible notes due 2031 to refinance nearer-term debt. Looking ahead, Evolent guided Q3 revenue to $460 million to $480 million and raised its full-year adjusted EBITDA outlook to $140 million to $165 million, with management pointing to an accelerating pipeline as a catalyst for growth in 2026.
- Rising medical costs impacting health plans driving demand for complex specialty care solutions
- Adjusted EBITDA margin expansion to 8.5% from 8.0% year-over-year
- Specialty Technology and Services Suite lives on platform grew to 77,019 thousand from 71,701 thousand
- Average Unique Members grew to 40,201 thousand from 39,856 thousand
“Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates for 2026. The combination of these factors we believe demonstrates Evolent's critical role in the system where our solutions seek to simultaneously improve quality for members, reduce administrative burden for providers and manage affordability for the system. Finally, as we mark the one-year anniversary of launching of Auth Intelligence, we remain confident in achieving the near-term AI and automation targets exiting 2025 while also seeing a path to become a leader in the market on the use of clinical data exchange and AI allowing us to continue to innovate on how specialty care is managed.”
Evolent Health CEO, on the earnings call
Forward Guidance & Outlook
For Q3 2025, Evolent expects revenue of $460 million to $480 million and adjusted EBITDA of $34 million to $42 million. For full year 2025, the company raised its adjusted EBITDA guidance to approximately $140 million to $165 million, while revising revenue guidance to approximately $1.85 billion to $1.88 billion to reflect updated go-live timing for certain Performance Suite launches. The company expects approximately $35 million in capitalized software development during 2025. Management highlighted strong customer retention, late-stage pipeline activity, and expects to exceed historical growth rates in 2026 based on pipeline acceleration.
EVH YoY Financials
EVH Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.